Cover Image
市場調查報告書

美國的導管固定器具市場

US Market Report for Catheter Securement Devices - MedCore

出版商 iData Research Inc. 商品編碼 360652
出版日期 內容資訊 英文 161 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的導管固定器具市場 US Market Report for Catheter Securement Devices - MedCore
出版日期: 2016年05月01日 內容資訊: 英文 161 Pages
簡介

本報告提供美國的導管固定器具市場相關調查分析,提供您疾病概要,產品的評估,市場分析與預測,推動市場要素與阻礙要素,競爭分析等相關的系統性資訊。

第1章 摘要整理

第2章 調查手法

第3章 疾病概要

  • 基本結構
  • 血管病變·障礙
  • 患者的人口統計
    • 癌症
    • 末期腎功能衰竭
    • 糖尿病

第4章 產品的評估

  • 產品系列
    • 導管固定器具

第5章 導管固定器具市場

  • 銷售額件數分析
  • 市場分析與預測
  • 趨勢分析
  • 推動因素·阻礙因素
    • 推動市場要素
    • 市場阻礙因素
  • 競爭市場佔有率分析

圖表

目錄
Product Code: iDATA_USVA16_MC_CS

The total U.S. market for catheter securement comprises tape, dressings, sutures and MCSDs used to secure vascular access devices. In addition to securing catheters, products such as tape and dressings are also used for all types of wound care. This analysis will cover only the market for securement mechanisms used in combination with vascular access devices.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

  • 1.1. U.S. VASCULAR ACCESS DEVICES AND ACCESSORIES MARKET OVERVIEW
  • 1.2. COMPETITIVE LANDSCAPE
  • 1.3. MARKET TRENDS
  • 1.4. KEY MARKET DEVELOPMENTS
  • 1.5. MARKETS INCLUDED
  • 1.6. PROCEDURES INCLUDED
  • 1.7. PROCEDURE CODES INVESTIGATED
  • 1.8. KEY REPORT UPDATES
  • 1.9. VERSION HISTORY

RESEARCH METHODOLOGY

  • 2.1. RESEARCH SCOPE
  • 2.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 3.1. BASIC ANATOMY
    • 3.1.1. Human Vascular System
  • 3.2. VASCULAR PATHOLOGY AND DISORDERS
    • 3.2.1. Cancer
    • 3.2.2. End-Stage Renal Disease
    • 3.2.3. Diabetes
  • 3.3. PATIENT DEMOGRAPHICS
    • 3.3.1. Cancer
      • 3.3.1.1. Digestive Cancer
      • 3.3.1.2. Genital Cancer
      • 3.3.1.3. Breast Cancer
      • 3.3.1.4. Respiratory Cancer
      • 3.3.1.5. Urinary Cancer
      • 3.3.1.6. Skin Cancer
      • 3.3.1.7. Lymphoma
      • 3.3.1.8. Endocrine System Cancer
      • 3.3.1.9. Leukemia
      • 3.3.1.10. Oral Cavity/Larynx
      • 3.3.1.11. Myeloma
      • 3.3.1.12. Brain/Other Nervous System
      • 3.3.1.13. Soft Tissue (including heart)
      • 3.3.1.14. Bones and Joints
      • 3.3.1.15. Eye and Orbit
    • 3.3.2. End-Stage Renal Disease
      • 3.3.2.1. End-Stage Renal Disease Incidence
        • 3.3.2.1.1. End-Stage Renal Disease Incident Cases by Modality
        • 3.3.2.1.2. End-Stage Renal Disease Incident Cases by Age Group
        • 3.3.2.1.3. End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy
      • 3.3.2.2. Vascular Access Use at Hemodialysis Initiation
        • 3.3.2.2.1. Vascular Access Use During First Year of Hemodialysis
          • 3.3.2.2.1.1. Vascular Access Use During First Year of Hemodialysis by Age Group
          • 3.3.2.2.1.2. Vascular Access Use During First Year of Hemodialysis by Sex
        • 3.3.2.3. End-Stage Renal Disease Prevalence
          • 3.3.2.3.1. End-Stage Renal Disease Prevalent Cases by Modality
            • 3.3.2.3.1.1. Prevalent Hemodialysis Patients by Vascular Access Type
          • 3.3.2.3.2. End-Stage Renal Disease Prevalent Cases by Age Group
          • 3.3.2.3.3. End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy
    • 3.3.3. Diabetes
      • 3.3.3.1. Diagnosed Diabetes Incidence Amongst Adults
        • 3.3.3.1.1. Diagnosed Diabetes Incidence Amongst Adults by State
      • 3.3.3.2. Diagnosed Diabetes Prevalence Amongst Adults
        • 3.3.3.2.1. Diagnosed Diabetes Prevalence Amongst Adults by Medication Status
        • 3.3.3.2.2. Diagnosed Diabetes Prevalence Amongst Adults by State and Age Group
        • 3.3.3.2.3. Diagnosed Diabetes Prevalence Amongst Adults by State and Gender

PRODUCT ASSESSMENT

  • 4.1. PRODUCT PORTFOLIOS
    • 4.1.1. Catheter Securement Devices
      • 4.1.1.1. Introduction
        • 4.1.1.1.1. Catheter Stabilization Methods
      • 4.1.1.2. 3M
        • 4.1.1.2.1. 3M™ PICC/CVC Securement Systems
        • 4.1.1.2.2. Tegaderm™
        • 4.1.1.2.3. 3M™ Medical Tapes
      • 4.1.1.3. Baxter
        • 4.1.1.3.1. VITAL-HOLD™
      • 4.1.1.4. Cardinal Health
        • 4.1.1.4.1. Original Boarder
        • 4.1.1.4.2. Advanced IV
      • 4.1.1.5. Centurion Medical
        • 4.1.1.5.1. SorbaView®
        • 4.1.1.5.2. Other Product Offerings
      • 4.1.1.6. C.R. Bard
        • 4.1.1.6.1. StatLock® IV
        • 4.1.1.6.2. StatLock® PICC
        • 4.1.1.6.3. StatLock® CV
        • 4.1.1.6.4. StatLock® Dialysis
        • 4.1.1.6.5. Other StatLock® Offerings
      • 4.1.1.7. Insightra Medical
        • 4.1.1.7.1. Modulare®
      • 4.1.1.8. Interrad Medical
        • 4.1.1.8.1. SecurAcath®
      • 4.1.1.9. Johnson & Johnson
        • 4.1.1.9.1. BioPatch®
        • 4.1.1.9.2. Other Product Offerings
      • 4.1.1.10. M.C. Johnson
        • 4.1.1.10.1. CATH-SECURE™
      • 4.1.1.11. Medtronic
        • 4.1.1.11.1. Kendall™
        • 4.1.1.11.2. Other Product Offerings
      • 4.1.1.12. Neo Medical
        • 4.1.1.12.1. V-Lock™
      • 4.1.1.13. Smith & Nephew
        • 4.1.1.13.1. IV3000®
        • 4.1.1.13.2. HYPAFIX®
        • 4.1.1.13.3. PRIMAPORE®
      • 4.1.1.14. Starboard Medical
        • 4.1.1.14.1. CLIK-IT™
      • 4.1.1.15. TIDI Products
        • 4.1.1.15.1. Grip-Lok® PICC Securement
        • 4.1.1.15.2. Grip-Lok® CVC Securement
        • 4.1.1.15.3. Grip-Lok® PIVC Securement

CATHETER SECUREMENT DEVICE MARKET

  • 5.1. UNIT ANALYSIS
    • 5.1.1. Securement Market Unit Sales by Securement Type
      • 5.1.1.1. Catheters Secured with a Manufactured Securement Device by Catheter Type
  • 5.2. MARKET ANALYSIS AND FORECAST
    • 5.2.1. Total Catheter Securement Market
      • 5.2.1.1. Securement Device Market
  • 5.3. TREND ANALYSIS
    • 5.3.1. Catheter Securement Market
    • 5.3.1. Trends in Suture Stabilization
    • 5.3.2. Trends in Dressing Securement
  • 5.4. DRIVERS AND LIMITERS
    • 5.4.1. Market Drivers
    • 5.4.2. Market Limiters
  • 5.5. COMPETITIVE MARKET SHARE ANALYSIS
    • 5.5.1. Catheter Securement Market
      • 5.5.1.1. Manufactured Catheter Securement Device Market

LIST OF CHARTS

  • Chart 0-1: Vascular Access Device Market by Segment, U.S., 2012-2022
  • Chart 0-2: Vascular Access Device Market Overview, U.S., 2015 and 2022
  • Chart 3-1: Male Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-2: Male Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-3: Female Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-4: Female Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-5: Male Incidence, Genital Cancer, U.S., 2016
  • Chart 3-6: Male Deaths, Genital Cancer, U.S., 2016
  • Chart 3-7: Female Incidence, Genital Cancer, U.S., 2016
  • Chart 3-8: Female Deaths, Genital Cancer, U.S., 2016
  • Chart 3-9: Incidence by Gender, Breast Cancer, U.S., 2016
  • Chart 3-10: Deaths by Gender, Breast Cancer, U.S., 2016
  • Chart 3-11: Male Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-12: Male Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-13: Female Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-14: Female Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-15: Male Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-16: Male Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-17: Female Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-18: Female Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-19: Male Incidence, Skin Cancer, U.S., 2016
  • Chart 3-20: Male Deaths, Skin Cancer, U.S., 2016
  • Chart 3-21: Female Incidence, Skin Cancer, U.S., 2016
  • Chart 3-22: Female Deaths, Skin Cancer, U.S., 2016
  • Chart 3-23: Male Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-24: Male Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-25: Female Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-26: Female Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-27: Male Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-28: Male Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-29: Female Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-30: Female Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-31: Male Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-32: Male Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-33: Female Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-34: Female Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-39: Incidence by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-40: Deaths by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-43: Incidence by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-44: Deaths by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-45: Incidence by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-46: Deaths by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-49: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Chart 3-50: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Chart 3-51: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Chart 3-52: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015 83
  • Chart 3-53: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Chart 3-54: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Chart 3-55: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Chart 3-56: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Chart 3-57: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Chart 3-58: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Chart 3-59: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Chart 3-60: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Chart 3-61: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Chart 5-1: Securement Market Unit Sales by Securement Type, U.S., 2015
  • Chart 5-2: Total Catheter Securement Market, U.S., 2012-2022
  • Chart 5-3: Manufactured Catheter Securement Market, U.S., 2012-2022
  • Chart 5-4: Leading Competitors, Catheter Securement Market, U.S., 2015
  • Chart 5-5: Leading Competitors, Manufactured Catheter Securement Device Market, U.S., 2015

LIST OF FIGURES

  • Figure 0-1: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2)
  • Figure 0-2: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2)
  • Figure 0-3: Companies Researched in Report, U.S., 2015
  • Figure 0-4: Factors Impacting the Vascular Access Device and Accessories Market by Segment, U.S.
  • Figure 0-5: Recent Events in the Vascular Access Device and Accessories Market, U.S., 2012-2015
  • Figure 0-6: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (1 of 3)
  • Figure 0-7: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (2 of 3)
  • Figure 0-8: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (3 of 3)
  • Figure 0-9: Vascular Access Devices & Accessories Procedures Covered, U.S., 2015
  • Figure 0-10: Procedural Codes, U.S., 2015
  • Figure 0-11: Key Report Updates, U.S., 2014 and 2016 (1 of 2)
  • Figure 0-12: Key Report Updates, U.S., 2014 and 2016 (2 of 2)
  • Figure 0-13: Version History
  • Figure 3-1: Digestive Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-2: Genital Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-3: Breast Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-4: Respiratory Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-5: Urinary Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-6: Skin Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-8: Endocrine Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-9: Leukemia Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-11: Myeloma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-13: Soft Tissue (Including Heart) Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-15: Eye and Orbit Statistics by Type and Gender, U.S., 2016
  • Figure 3-16: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Figure 3-17: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Figure 3-18: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Figure 3-19: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-20: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Figure 3-21: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Figure 3-22: Vascular Access Use During First Year of Hemodialysis by Age Group, U.S., 2013-2014
  • Figure 3-23: Vascular Access Use During First Year of Hemodialysis by Sex, U.S., 2013-2014
  • Figure 3-24: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Figure 3-25: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Figure 3-26: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Figure 3-27: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Figure 3-28: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-29: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Figure 3-30: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (1 of 2)
  • Figure 3-31: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (2 of 2)
  • Figure 3-32: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Figure 3-33: Diagnosed Diabetes Prevalence Count Adults by Medication Status, U.S., 1997-2015
  • Figure 3-34: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (1 of 2)
  • Figure 3-35: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (2 of 2)
  • Figure 3-36: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (1 of 2)
  • Figure 3-37: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (2 of 2)
  • Figure 5-1: Securement Market Unit Sales by Securement Type, U.S., 2015
  • Figure 5-2: Percentage of Catheters Secured with a Manufactured Securement Device by Catheter Type, U.S., 2015
  • Figure 5-3: Total Catheter Securement Market, U.S., 2012-2022
  • Figure 5-4: Manufactured Catheter Securement Market, U.S., 2012-2022
  • Figure 5-5: Drivers and Limiters, Catheter Securement Device Market, U.S., 2015
  • Figure 5-6: Leading Competitors, Catheter Securement Market, U.S., 2015
  • Figure 5-7: Leading Competitors, Manufactured Catheter Securement Device Market, U.S., 2015
Back to Top